Introduction
Chronic obstructive pulmonary disease (COPD) is a disorder characterized by the progressive development of airway obstruction, which manifests as an 1 Treatments aim to prevent and control symptoms, reduce exacerbations, improve health status, and increase exercise tolerance. Currently, the Global Initiative for Chronic Obstructive Lung Disease recommend initiation with a short-acting bronchodilator followed by the addition of long-acting bronchodilators as the disease progresses. 1 Commonly used bronchodilators include inhaled long-acting β 2 -agonists (LABAs) (eg, formoterol or salmeterol), the inhaled long-acting anticholinergic tiotropium, and oral methylxanthines. 1 If a patient with severe disease experiences repeated exacerbations, an inhaled steroid may be added and fixed-dose combinations (FDC) of LABA plus an inhaled steroid, including formoterol/ budesonide (FOR/BUD) or salmeterol/fluticasone proprionate (SAL/FP), may be prescribed. 1 Despite recommendations, it has been found that a high percentage of patients receive FDCs as a first-line treatment. 2 Indacaterol is a novel once-daily inhaled LABA indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with COPD. The recommended dose is one 150 microgram (µg) capsule once a day, using the Onbrez ® Breezhaler ® (Novartis) inhaler, increased on medical advice to a maximum dose of one 300 µg capsule once a day. 3 In an extensive phase III clinical trial program indacaterol demonstrated superior lung function to LABA monotherapies and was at least as good as LABAs with respect to other outcomes. [4] [5] [6] [7] Given these findings, and the knowledge of the early use of FDCs, a comparison of indacaterol to FDCs is a relevant clinical question.
In the absence of a head-to-head randomized controlled trial (RCT) for the comparison of interest, the objective of the current study was to indirectly compare the efficacy of indacaterol 150 µg, indacaterol 300 µg, fixed-dose FOR/ BUD, and fixed-dose SAL/FP for the treatment of COPD patients based on the currently available RCT evidence by means of a network meta-analysis. Outcomes of interest were lung function measured by trough forced expiratory volume in 1 second (FEV 1 ), health status measured by the St. George's Respiratory Questionnaire (SGRQ) total score, and breathlessness as assessed by transition dyspnea index (TDI) total score.
Methods

Identification and selection of studies
A systematic literature search was performed using a predefined search strategy in MEDLINE ® and EMBASE ® ; study documents for indacaterol studies were provided by Novartis. Search terms included a combination of free-text and thesaurus terms relevant to COPD, indacaterol, salmeterol, formoterol, and RCTs (see Appendix for search strategy). The search strategy was initially performed for the period 1989-2009 and a supplementary search was undertaken for the period 2009-2010 in order to capture the most recent literature. Two reviewers independently evaluated each identified study against the following predetermined criteria:
• Population of interest: adults with COPD.
• Interventions: indacaterol 150 µg or 300 µg, fixed dose combinations of FOR/BUD and SAL/FP.
• Comparators: comparators included any of the interventions or placebo. Studies that solely evaluated different components of the fixed dose combination separately were excluded.
• Outcomes: outcomes of interest included trough FEV 1 (reported predose values) at 12 weeks and 6 months, SGRQ total score at 6 months, and TDI total score at 6 months.
• Study design: RCTs.
For the studies identified that met the selection criteria, details were extracted on study design, population characteristics, interventions, and the outcomes trough FEV 1 at 12 weeks and 6 months, SGRQ total score at 6 months, and TDI total score at 6 months. Only outcomes that were within 2 weeks of the time point of interest were extracted. For each outcome the difference in the change from baseline (CFB) (or difference at follow-up adjusted for baseline) was extracted where reported. In cases where the difference in CFB was not reported, it was calculated by subtracting the CFB in the placebo from the CFB in the active treatment (or the adjusted CFB values). If the CFB values per treatment were not reported they were extracted from figures using the software DigitizIt version 1.5.8. The standard error of the difference in CFB was extracted where available or calculated based on the uncertainty or variation reported (eg, 95% confidence interval or standard deviation). If there was insufficient information to calculate the standard error of the difference, an average standard deviation was calculated from the studies included in each specific analysis and combined with the study-specific sample size to derive the standard error. at 6 months, the CFB in SGRQ total score at 6 months, and the TDI total score at 6 months, to simultaneously synthesize the results of the included studies and to obtain differences for indacaterol 150 and 300 µg versus FOR/BUD, SAL/FP, and placebo.
Network meta-analyses within the Bayesian framework involve data, a likelihood distribution, a model with parameters, and prior distributions. 10 The model relates the data from the individual studies to basic parameters reflecting the (pooled) relative treatment effect of each intervention compared to an overall reference treatment, eg, placebo. Based on these basic parameters, the relative efficacy between each of the competing interventions was obtained. For all endpoints a regression model with a normal likelihood distribution was used. 9, 10 For each outcome, a fixed and a random effects model was evaluated. The fixed effects model assumes that the differences in true relative treatment effects across studies in the network of evidence are caused only by the differences in treatment comparisons. The random effects model assumes that differences in observed treatment effects across the studies in the network are not only caused by the different treatment comparisons, but that there is also heterogeneity in the relative effects for a particular type of comparison caused by factors that modify that relative treatment effect. A comparison of the fit of the fixed and random effects model to the data based on the residual deviance was used to select a fixed or random effects model.
11
With a network meta-analysis, randomization only holds within a trial and not across trials. As a result, there is the risk that patients who were studied in different comparisons are not similar, which leads to consistency violations. In order to minimize confounding bias, treatment by covariate interactions were incorporated in the models. 12 Covariates potentially causing bias were selected based on clinical expertise and evaluation of whether these covariates were effect modifiers of any of the treatments under evaluation in individual studies analyzed. The following covariates were included simultaneously where possible and otherwise in separate models where insufficient data were available: 1) Proportion of patients who are current smokers (as opposed to ex-smokers); and 2) Proportion of patients with severe or very severe COPD (as opposed to mild or moderate COPD). Additional analyses were also performed, including study level covariates for age, and sex; which were not presented given the limited impact of the treatment by covariate interactions.
The results of the network meta-analysis provide relative treatment effects of each treatment versus a competing intervention, eg, differences in TDI or the differences in the CFB for FEV 1 or SGRQ. In order to transform these relative estimates into absolute expected results with each treatment (eg, TDI or CFB in FEV 1 or SGRQ), the relative treatment effects of each regimen relative to placebo were combined with absolute average treatment effect for placebo as a reference.
The Bayesian approach involves a formal combination of a prior probability distribution, with a likelihood distribution for the model parameters to obtain a posterior probability distribution for the estimates of the basic parameters. In order to avoid prior beliefs influencing the results of the model, noninformative prior distributions were used. Prior distributions of the relative treatment effects were normal distributions with mean 0 and a variance of 10 6 . A uniform distribution with range of 0 to 2 was used for the prior distribution of heterogeneity for the random effects models. The posterior distribution can be interpreted in terms of probabilities and permits calculation of the probability that each treatment is best out of those compared given the data at hand; this gives the Bayesian approach an advantage over the frequentist approach. WinBUGS 1.4.1 statistical software was used for the analyses. 13 Summary statistics are presented for the expected absolute and relative treatment effects. In addition to point estimates reflecting the most likely value, 95% credible intervals (95% CrI) reflecting the range of true underlying effects with 95% probability are presented. Furthermore, for each of the endpoints, the probability that indacaterol is better than a certain regimen is presented. Results are presented without adjustment for covariates for the CFB in FEV 1 at 12 weeks and 6 months, CFB in SGRQ total score at 6 months, and TDI total score at 6 months. Results with adjustment are discussed for FEV 1 at 12 weeks. The inclusion of covariates was explored for SGRQ and TDI, but was not always feasible given the data limitations.
Results
Study selection and characteristics
The literature search identified 411 potentially relevant studies ( Figure 1 ). The first review excluded 375 (91%) of these abstracts because of the trial design (117, 28%), intervention (107, 26%), trial duration (60, 15%), duplication (47, 11%), comparator (24, 6%) , and population (20, 5% 9 FDCs trials + 6 indacaterol trials (11 publications + 6 CSRs) Figure 1 Flow diagram of study selection. Abbreviations: CSR, complete study reports; FDC, fixed-dose combinations; PICOS, patients, interventions, comparators, outcomes, and study design.
Data on file were used for studies B2334 27 and B2346, 28 which corresponded to publications by Dahl et al 2010 4 and Feldman et al 2010, 6 respectively. The network of evidence ( Figure 2 ) illustrates that all active therapies were compared to placebo, and that 3 studies directly compared indacaterol 150 µg to indacaterol 300 µg. Study B2334 evaluated indacaterol 300 µg and 600 µg once daily compared to placebo and formoterol 12 µg twice daily over 52 weeks. This was the first pivotal indacaterol registration study, and in addition to data on the 300 µg dose, it provides safety data on the 600 µg dose -a dose that is 2 to 4 times the EU-approved dose. B2335S was an adaptive seamless design study that combined an initial dose-selection phase with a pivotal registration phase and assessed indacaterol 150 µg and 300 µg once daily compared to placebo and open-label tiotropium 18 µg once daily over 26 weeks. B2346 evaluated indacaterol 150 µg once daily compared to placebo over 12 weeks, and was the third indacaterol pivotal registration study (providing the required replicate data for the 150 µg dose), while B2336 compared indacaterol 150 µg once daily to placebo as well as salmeterol 50 µg twice daily over 26 weeks, providing additional data on the 150 µg dose.
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Barnes et al 14 Calverley et al 15 Calverley et al 16 Mahler et al 19 Zheng et al 22 Tables 1 and 2 present the details of the study and patient characteristics for the 15 studies included in the analysis. All studies were multicenter placebo-controlled RCTs with a parallel design and included a total of 10,211 adult patients with COPD. The studies included patients $40 years of age with FEV 1 /FVC of #0.70 and FEV 1 percent predicted ,80%, while the indacaterol trials required patients to have a predicted FEV 1 of at least 30%. Most studies included patients who were current or ex-smokers with a smoking history of at least 10 years, although some studies included patients with a smoking history of at least 20 pack-years (Hanania et al 2003, 18 Mahler et al 2002, 19 B2334, 4 B2335S, 5 B2336, 7 and B2346 6 ). Three studies included predominantly Asian patients (Zheng et al 2007, 22 and studies B1302 23 and B2333 24 ), whereas the remaining studies included mostly Caucasian patients or reported study centers in Europe and North America. Limited information was reported on the comorbidities of the patients, although most studies excluded patients with asthma or other respiratory or pulmonary diseases and other clinically significant diseases that may have affected treatment. Some differences across the studies were observed in baseline FEV 1 and health status (as assessed by SGRQ total score), which may have been related to COPD severity.
Comparative efficacy
In Table 3 the individual study results for the different endpoints are presented. These study findings were synthesized in 2 series of network meta-analyses: the first analyses included all studies and the second analyses excluded the 3 Asian studies. As patients using background inhaled corticosteroids (ICS) were permitted entry into the indacaterol studies (providing they continued to use ICS at a stable dose and regimen throughout the study), only data for patients not using ICS ('non-ICS users') were included in the analyses in order to ensure the patients in the placebo arms of the indacaterol trials were sufficiently similar to those in the FDC studies. Therefore, the analysis was based on unpublished subgroup data provided by Novartis for all indacaterol studies.
Trough Fev 1 at 12 weeks and 6 months All treatments were more efficacious than placebo at 12 weeks and 6 months in terms of trough FEV 1 for all analyses without The studies genearlly excluded patients that had a 'clinically signficiant condition' or 'significant medical disorder' that may have interfered with the study results. For example the protocol for study B2334 indicated the following exclusion: patients who, in the judgment of the investigator or the responsible Novartis personnel, had a clinically relevant laboratory abnormality or a clinically significant condition or any condition which in the investigator's opinion might have compromised patient safety or compliance, interfered with evaluation, or precluded completion of the study; covariates (Table 4 ). In the analysis including all studies (without covariates), indacaterol 150 µg resulted in higher FEV 1 compared to both FOR/BUD 9/160 µg and FOR/ BUD 9/320 µg at both time points (see Table 5 ). Results for indacaterol 300 µg were similar to indacaterol 150 µg, demonstrating a more favorable FEV 1 improvement than both doses of FOR/BUD (see Table 6 ). In comparison to SAL/FP 50/500 µg, indacaterol 150 µg and 300 µg were comparable in terms of FEV 1 at both time points. This was also the case for indacaterol 150 µg and 300 µg versus SAL/FP 50/250 µg at 12 weeks and at 6 months. The results were not sensitive to the exclusion of the 3 Asian studies, and only minor differences between the 2 analyses were observed in FEV 1 results (≈0.01 L associated with indacaterol 150 µg and 300 µg) in most cases (see Tables 5 and 6 ). Figure 3 illustrates the impact of adjusting for differences in the proportion of current smokers and patients with severe or very severe COPD on the relative results of indacaterol 150 µg versus the alternatives for FEV 1 at 12 weeks for both scenarios (all studies included and 3 Asian studies excluded). Indacaterol 150 µg was more efficacious than FOR/BUD 9/160 µg in most of the scenarios. The increase associated with indacaterol 150 µg in comparison to FOR/ BUD 9/320 µg varied from 0.09 L (95% CrI: to −0.02, 0.21) to 0.10 L (95% CrI: 0.02, 0.17) and was most sensitive to the proportion of patients with severe COPD (where the credible internals included zero). Indacaterol 150 µg and 300 µg remained comparable to SAL/FP 50/500 µg. Again, the lowest relative benefits associated with indacaterol were observed when adjusted for severity or both severity and smoking status.
SGRQ total score at 6 months
In the scenario with all studies included (without covariates), all active treatments were more efficacious than placebo, with the exception of FOR/BUD 9/160 µg which included zero in the credible intervals (see Table 4 ). No data were available for SAL/FP 50/250 µg for SGRQ at 6 months. When the 3 Asian studies were excluded from the analysis, SAL/FP 50/500 µg was no longer more efficacious than placebo (as the CrI included zero). Based on the analysis of all studies without covariates, indacaterol 150 µg resulted in comparable improvement in SGRQ total score versus SAL/FP 50/500 µg, FOR/BUD 9/160 µg and FOR/BUD 9/320 µg, showing a trend towards better scores (2.16 points, 1.48 points, and 0.39 points improvement, respectively) (see Table 5 ). Indacaterol 300 µg resulted in lower scores than indacaterol 150 µg, but remained comparable to the alternative treatments submit your manuscript | www.dovepress.com
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Efficacy of indacaterol versus fixed-dose combinations: a network meta-analysis Table 3 Reported data in individual studies included in the network meta-analysis (see Table 6 ). As with FEV 1 , excluding the Asian studies had minimal impact on the results and improved the point estimates in favor of indacaterol.
TDI total score at 6 months All treatments were more efficacious than placebo for TDI (see Table 4 ). Comparative estimates versus FOR/BUD were not possible at 6 months given the lack of data. Comparable results were observed for indacaterol and SAL/FP in the analyses without covariates (see Tables 5 and 6 ). Indacaterol 150 µg and 300 µg demonstrated slightly higher TDI scores compared to SAL/FP 50/250 µg, with an improvement of 0.21 points and 0.39 points, respectively. However, compared to SAL/FP 50/500 µg, indacaterol 150 µg and 300 µg had slightly lower TDI scores, with point estimates of −0.69 points and −0.51 points, respectively. Consistent results were observed in the scenario without the Asian studies, although the point estimates improved slightly for indacaterol and the CrI widened, since the number of studies included in the analysis was reduced from 6 to 5.
Discussion
The objective of this study was to compare the efficacy of indacaterol 150 µg and 300 µg once daily versus fixed-dose combinations FOR/BUD and SAL/FP twice daily for COPD in terms of trough FEV 1 , SGRQ total score and TDI total score. In terms of trough FEV 1 , all treatments were better than placebo. At 12 weeks, indacaterol 150 and 300 µg were more efficacious than FOR/BUD 9/160 µg, at least as efficacious as FOR/BUD 9/320 µg, and comparable to SAL/FP (50/250 and 50/500 µg). Results were consistent at 6 months and therefore both indacaterol doses are expected to be at least comparable to the fixed-dose combinations for this parameter. The probability that the FEV 1 was higher for patients receiving indacaterol 150 or 300 than for each active comparator ranged from 51% to 99%. For SGRQ total score at 6 months, results suggest that indacaterol provides a comparable SGRQ improvement to the fixed-dose combinations for FOR/BUD (both doses) and SAL/FP 50/500 µg. In terms of TDI total score at 6 months, the results did support the efficacy of all treatments compared to placebo. Again, results indicate that indacaterol was comparable to both doses of SAL/FP for which data were available. Differences in SGRQ and TDI scores did not reach a clinically meaningful level (eg, less than SGRQ 4 points 29 and less than TDI 1 points 30 ), which suggests that indacaterol offers a comparable level of symptom relief to the fixed-dose combinations evaluated. As with previous analyses, improvements in TDI were more pronounced for indacaterol 300 µg compared to indacaterol 150 µg. In a separate analysis of pooled data, this additional improvement with the 300 µg dose was particularly apparent in patients with severe COPD.
Efficacy of indacaterol versus fixed-dose combinations: a network meta-analysis Table 5 Results of network meta-analysis; Indacaterol 150 µg versus alternatives without covariates 
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Cope et al Table 6 Results of network meta-analysis: indacaterol 300 µg versus alternatives without covariates In a network meta-analysis of RCTs involving multiple treatment comparisons, the randomization holds only within the individual trials, and not across trials. If the trials differ among the direct comparisons for study and patient characteristics, and these differences are modifiers of the relative treatment effects, then the estimate of the indirect and mixed comparisons is biased.
12
In the indacaterol studies patients were allowed to continue receiving concurrent ICS, which was not the case in the FOR/BUD and SAL/FP studies. To avoid biased estimates of indacaterol versus FOR/BUD and SAL/FP a subgroup of patients who did not receive an ICS in indacaterol studies was evaluated in the network meta-analysis.
Differences were identified in terms of the proportion of males, the average age, the proportion of current smokers, and the proportion of patients with severe or very severe COPD in the indacaterol studies (subgroup) compared to the patients in the other studies. To evaluate the extent of the effect these differences in patient characteristics had on the relative effect estimates, meta-regression models were used. Although it was not feasible to include all of the covariates of interest simultaneously due to the limited amount of data, where possible the proportion of current smokers and the proportion of patients with severe or very severe COPD were included in one model. Results adjusted for the proportion of males and the average age had only a marginal impact on the effect estimates, and are therefore not believed to be a likely source of bias in the unadjusted analysis. Adjustment for smoking status and COPD severity had a greater impact on the relative effect estimates (see Figure 3 ), but the differences between adjusted and unadjusted models were not greater than the amount of uncertainty in the estimates. As such, adjusted and unadjusted models lead to the same interpretation of the findings. Although the meta-regression analyses suggest that the results of the network meta-analysis are not likely to be greatly affected by similarity and consistency violations, it was not possible to assess the similarity of the studies in terms of all patient characteristics. For example, limited information was presented for the comorbidities of patients across the trials. Therefore, it has to be accepted that with aggregate level data there is the risk of residual confounding bias.
Since the studies did not consistently report the ethnicity of the patients or report subgroup data, it was not feasible to include a covariate to adjust for differences in ethnicity. However, studies included a predominantly Caucasian population, and all studies were combined in the analysis. An additional analysis with 3 Asian studies excluded resulted in similar estimates and suggests that ethnicity is not a factor of importance in the current evidence base.
In conclusion, indacaterol monotherapy (150 µg and 300 µg) (no concomitant ICS) is expected to be at least as good as FOR/BUD (9/320 and 9/160 µg) and comparable to submit your manuscript | www.dovepress.com
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Cope et al SAL/FP (50/250 and 50/500 µg) with respect to lung function (trough FEV 1 ). Indacaterol monotherapy (150 and 300 µg) is also expected to provide comparable efficacy in terms of health status (SGRQ total score) versus FOR/BUD (9/320 and 9/160 µg) and SAL/FP 50/500 µg, as well as similar improvements in breathlessness (TDI total score) as SAL/ FP (50/250 and 50/500 µg).
